A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
A legfontosabb adatok
- Ki végzi
- Takeda
- Hol
- Beijing, Chengdu, Guangzhou, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Tianjin, Wuhan, Xi'an és Zhengzhou (Kína)Mind a 16 helyszín megnézéseMég 19 másik országban, 113 helyszínen
- Azonosító
- NCT06948318
- EU 2025-521692-31-00
- JRCT2031250237
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 150 fő, tervezett
- Kezdés
- 2025. aug. 14.
- Várható befejezés
- 2029. júl. 29.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Mezagitamab
- A regiszteradat frissítve
- 2026. október 30.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with chronic primary immune thrombocytopenia (ITP) who completed the earlier mezagitamab studies TAK-079-3002 or TAK-079-1004.
- Életkor
- 18 years and older
- Nem
- All sexes
- A betegség stádiuma
- Chronic primary immune thrombocytopenia (low platelets caused by the immune system).
- Korábbi kezelés
- People must have completed TAK-079-3002 or TAK-079-1004 to the end of the trial. People from TAK-079-1004 must have had a platelet response to mezagitamab in that trial.
A részvétel fő kizáró okai
- Severe allergic reaction to recombinant proteins or ingredients in the mezagitamab product
- From TAK-079-1004: blood clot event within 12 months, or spleen removal within 3 months
- From TAK-079-1004: active hepatitis B, hepatitis C or HIV infection
- From TAK-079-1004: cancer within 5 years, except treated non-melanoma skin cancer or cervical carcinoma in situ
- From TAK-079-1004: recent anti-CD20 treatment, antibodies for the immune system, blood thinners, live vaccines or certain immune-suppressing drugs
A regiszter feltételei, szó szerint
Mind a 14 feltétel megnézéseKevesebb
Egyéb feltételek
- Key Inclusion Criteria:; The participant has completed TAK-079-3002 (end of trial [EOT]) or TAK-079-1004 (EOT). Participants from TAK-079-1004 must have had a response to mezagitamab as demonstrated by meeting the criteria for "platelet response" specified for that trial during either the main study or open-label extension
- Key Exclusion criteria:; For TAK-079-3002 participants:
- The participant has a history of severe allergic or anaphylactic reactions to recombinant proteins or excipients used in the mezagitamab formulation; For TAK-079-1004 participants:
- The participant has had any thrombotic or embolic event within 12 months before signing the ICF
- The participant has had a splenectomy within 3 months before signing the ICF
- The participant has active infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)
- History of malignancy (including myelodysplastic syndrome) within 5 years of signing the ICF, except for treated non-melanoma skin cancer or cervical carcinoma in situ
- In the opinion of the investigator, the participant has a serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol
- The participant has received anti-cluster of differentiation (CD) 20 treatment within 12 months before screening and either of the following applies:; The last dose was received within 6 months before screening; The last dose was received between 6 and 12 months before screening and the participant has a CD19+ count below the lower limit of normal
- The participant has received any monoclonal or polyclonal antibody for immunomodulation within 6 months before Visit 1
- The participant has been exposed to another investigational agent within 4 weeks or 5 half-lives, whichever is longer, before Visit 1
- The participant has used anticoagulants (for example, vitamin K antagonists, direct oral anticoagulants) within 3 weeks prior to Visit 1; 10 The participant has received a live or live-attenuated vaccine within 4 weeks prior to the first dose of trial treatment or has any live or live-attenuated vaccine planned during the trial
- The participant has used the following immunosuppressive agents as specified prior to Visit 1: alkylating agents (for example, cyclophosphamide) within 8 weeks, vinca alkaloids (for example, vincristine) within 4 weeks, sulfones (for example, dapsone) within 3 weeks, antiproliferative agents: (for example, mycophenolate mofetil and azathioprine) within 2 weeks, and calcineurin inhibitors: (for example, cyclosporine) within 2 weeks
- The participant has a history of severe allergic or anaphylactic reactions to recombinant proteins or excipients used in the mezagitamab formulation; Other protocol defined inclusion/exclusion criteria may apply
Helyszínek itt: Kína
Még 19 másik országban, 113 helyszínen
- Peking Union Medical College HospitalBeijing, KínaContact: Tienan Zhu (principal investigator)Résztvevőt keres
- West China Hospital,Sichuan UniversityChengdu, KínaContact: Yuping Gong (principal investigator)Résztvevőt keres
- Guangdong Provincial People's HospitalGuangzhou, KínaContact: Chengwei Luo (principal investigator)Toborzás még nem indult
- Zhejiang Provincial Hospital of Chinese Medicine - MainHangzhou, KínaContact: Baodong Ye (principal investigator)Toborzás még nem indult
- Qilu Hospital of Shandong UniversityJinan, KínaContact: Ming Hou (principal investigator)Résztvevőt keres
- The Second Affiliated Hospital of Kunming Medical UniversityKunming, KínaContact: Zeping Zhou (principal investigator)Résztvevőt keres
- The First Affiliated Hospital of Nanchang University - Donghu CampusNanchang, KínaContact: Ruibin Huang (principal investigator)Résztvevőt keres
- The First Affiliated Hospital of Guangxi Medical UniversityNanning, KínaContact: Peng Cheng (principal investigator)Résztvevőt keres
- Jinshan Hospital of Fudan UniversityShanghai, KínaContact: Yunfeng Cheng (principal investigator)Résztvevőt keres
- Shengjing Hospital of China Medical University (Nanhu Campus)Shenyang, KínaContact: Aijun Liao (principal investigator)Toborzás még nem indult
- The First Hospital of Hebei Medical UniversityShijiazhuang, KínaContact: Qingchi Liu (principal investigator)Résztvevőt keres
- The First Affiliated Hospital of Soochow University - Shizijie CampusSuzhou, KínaContact: Jie Yin (principal investigator)Résztvevőt keres
- Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences - PPDSTianjin, KínaContact: Yunfei Chen (principal investigator)Résztvevőt keres
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, KínaContact: Yu Hu (principal investigator)Résztvevőt keres
- Shaanxi provincial people's hospitalXi'an, KínaContact: Yi Wang (principal investigator)Toborzás még nem indult
- Henan Cancer HospitalZhengzhou, KínaContact: Hu Zhou (principal investigator)Résztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a lower number of platelets, making it easier to bruise or bleed. The main aim of this study is to check how safe mezagitamab is and how well it is tolerated by adults with chronic primary ITP, if given over a longer time. Other aims are to learn how effective treatment with mezagitamab is and how the body processes it (called pharmacokinetics or PK) over a longer time.
A teljes eredeti leírásKevesebb
Participants of the following previous mezagitamab studies will be invited to join this continuation study: TAK-079-3002 and TAK-079-1004. In this continuation study, participants will receive mezagitamab when certain protocol criteria are met.
During the study, participants will visit their study clinic several times.
A vizsgálat csoportja
- MezagitamabA vizsgált kezelés
Eligible participants who completed the TAK-079-3002 or TAK-079-1004 studies can receive on-demand treatment in this continuation study. The on-demand treatment course may be repeated as needed based on the pre-specified on-demand dosing criteria and investigator's clinical judgement.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A Phase 3, Open-label, Multicenter Continuation Trial to Evaluate the Long-term Safety and Efficacy of Mezagitamab Subcutaneous Injection in Adults With Chronic Primary Immune Thrombocytopenia
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. október 30.